Cardiac Magnetic Resonance Imaging

Toward Clinical Risk Assessment in Hypertrophic Cardiomyopathy With Gadolinium Cardiovascular Magnetic Resonance

James C. C. Moon, MB, BC†,* William J. McKenna, FACC, FESC;† Jane A. McCrohon, FRACP, PhD,* Perry M. Elliott, MD, MRCP, FACC,† Gillian C. Smith, BSc,*† Dudley J. Pennell, MD, FRCP, FESC, FACC*

London, United Kingdom

OBJECTIVES

We sought to assess whether hyperenhancement by gadolinium cardiovascular magnetic resonance (CMR) occurs in hypertrophic cardiomyopathy (HCM) and correlates with the risk of heart failure and sudden death.

BACKGROUND

The myocardial interstitium is abnormal in HCM at post-mortem. Focally increased interstitial myocardial space appears as hyperenhancement with gadolinium CMR.

METHODS

In a blinded, prospective study, HCM patients were selected for the presence (n = 23) or absence (n = 30) of an increased clinical risk of sudden death and/or progressive adverse left ventricular (LV) remodeling. Gadolinium-enhanced CMR was performed.

RESULTS

Myocardial hyperenhancement was found in 42 patients (79%), affecting 10.9% (range 0% to 48%) of the LV mass. There was a greater extent of hyperenhancement in patients with progressive disease (28.5% vs. 8.7%, p < 0.001) and in patients with two or more risk factors for sudden death (15.7% vs. 8.6%, p < 0.02). Improved discrimination was seen in patients 40 years old (29.6% vs. 6.7%, p < 0.001) for progressive disease and for patients 40 years old for risk factors for sudden death (15.7% vs. 2.1%, p = 0.002). Patients with diffuse rather than confluent enhancement had two or more risk factors for sudden death (87% vs. 33%, p < 0.01).

CONCLUSIONS

Gadolinium CMR reveals myocardial hyperenhancement in HCM. The extent of hyperenhancement is associated with progressive ventricular dilation and markers of sudden death. (J Am Coll Cardiol 2003;41:1561–7) © 2003 by the American College of Cardiology Foundation

An important minority of patients with hypertrophic cardiomyopathy (HCM) are at high risk of sudden death and/or progressive left ventricular (LV) impairment (1,2). Predicting these outcomes is a major management challenge, and new methods are needed. The abnormal myocardial substrate is probably the key determinant of clinical events (3–6), consisting of interstitial fibrosis, myocardial disarray, small-vessel disease, and macroscopic scarring. Fibrosis caused by myocardial infarction can be detected by cardiovascular magnetic resonance (CMR) using the extra-cellular fluid tracer gadolinium-diethylenetriaminepentaacetic acid (DTPA), or gadolinium CMR (7–9). We hypothesized that abnormal myocardium would be demonstrated in vivo by hyperenhancement on gadolinium CMR in HCM and that hyperenhancement would be associated with markers of risk of sudden death and the presence of progressive disease.

METHODS

Patients. This was a blinded, prospective study of 53 patients selected from a dedicated HCM clinic at St. George’s Hospital, London, which consists of 1,074 patients. The selected patients fulfilled conventional criteria for HCM with left ventricular hypertrophy (LVH) ≥15 mm at some time point in their disease (10). The only exclusion criterion was the presence of an implantable device. We aimed to recruit approximately equal numbers of patients with two or more risk factors or progressive disease, as those without these factors. Four patients had undergone gradient reduction therapy (two surgical myectomies and two transcatheter alcohol ablations). All patients gave written, informed consent, and the institutional Ethical Review Committee approved the study.

Sudden death risk stratification. Five clinical risk factors for sudden death were used to stratify patients: a family history of HCM and sudden premature cardiac death;
unexplained syncope at any time during follow-up; non-
sustained ventricular tachycardia; an abnormal blood pressure response during upright exercise testing in subjects ≤40 years old; and echocardiographic presence of severe LVH ≥30 mm.

**Diagnosis of progressive disease.** Progressive disease was defined as a decrease in maximal LV wall thickness ≥5 mm and an increase in LV end-systolic dimension ≥5 mm during five or more years of follow-up on a serial in-house echocardiogram. This definition selects a poor prognostic group, including patients with “pseudonormalization” of initial supra-systolic function and LVH on the way to a dilated phase.

**The CMR technique.** CMR was performed on a 1.5-T Sonata scanner (Siemens, Erlangen, Germany). Fast imaging with steady-state precession (FISP) sequential short-axis cine loops (7-mm slice thickness, 3-mm gap) were acquired. A peripheral bolus injection of gadolinium-DTPA (0.1 mmol/kg) was then given, and contrast-enhanced images were acquired using a segmented inversion-recovery sequence (11), with the following modifications: imaging was started at 5 min; segmentation was from 17 to 23 lines; inversion pulse every 2 to 3 heart beats depending on the RR interval and heart rate variability; a 90° presaturation pulse was placed over the cerebrospinal fluid to eliminate ghosting; and two-chamber, four-chamber, and all short-axis views were acquired twice with different phase-encoding direction and meticulous attention to the inversion time. The typical voxel size was 1.7 × 1.4 × 8 mm.

**Image analysis.** Ventricular function was analyzed from the serial short-axis true FISP cine loops using manual segmentation (CMRtools Imperial College, London). End-diastolic volume, end-systolic volume, ejection fraction, and myocardial volume of the LV were calculated. For the gadolinium-enhanced images, hyperenhancement was only considered to be present if it was also present in the same slice after swapping phase encoding, thus excluding artifact. Analysis was performed by manually defining the areas of hyperenhancement on all short-axis slices from the base to apex. Summing the areas yielded the total volume of hyperenhancement, which was expressed as a percentage of total myocardium.

**Statistical analysis.** Non-parametric Wilcoxon rank comparisons were made to compare the extent of hyperenhancement between patients with ≤1 and ≥2 risk factors for sudden death, and between patients with and without the presence of progressive disease. Linear regression analysis was performed to compare the extent of hyperenhancement with patient age, LV function, and mass.

**RESULTS**

**Patient baseline characteristics.** The baseline characteristics of the patients are given in Table 1. There were 0, 1, 2, 3, 4, and 5 risk factors in 19, 16, 13, 3, 2, and 0 patients, respectively. Of 34 patients with >5 years of follow-up, nine had progressive disease (of these, four patients also had ≥2 risk factor for sudden death). There was no age difference between patients with and without progressive disease (49 vs. 51 years, p = 0.8), but patients with ≥2 risk factors for sudden death were younger than patients with ≥1 risk factors for sudden death (35 vs. 53 years, p < 0.001).

**Extent of hyperenhancement.** Myocardial hyperenhancement was present in 42 patients (79%). The mean percentage of myocardium involved was 10.9 ± 11% (range 0% to 48%). Abnormal myocardium was not visible without contrast (Fig. 1). Regions of hyperenhancement had a mean image intensity of 27; remote myocardium, 5.7; and background noise, 4.24. The percentage elevation in signal from hyperenhanced regions was 430% (range 120% to 1,000%); the mean difference in image intensity between hyperenhanced and remote regions was 16 standard deviations of remote region intensity. There was no relationship between percentage hyperenhancement and patient age (r = 0.1, p = 0.47). The percentage hyperenhancement correlated weakly with LV mass index (r = 0.24, p = 0.04), end-diastolic
There was more hyperenhancement in patients with progressive disease than in those without (28.5% vs. 8.7%, p < 0.001) (Fig. 2A). This remained significant when patients with ≥2 risk factors for sudden death were excluded (28.4% vs. 6.9%, p = 0.04) (Fig. 2B). There was greater hyperenhancement in patients with ≥2 risk factors for sudden death (15.7% vs. 8.6%, p = 0.02) (Fig. 3A). This finding appeared more marked in patients <40 years old (15.7% vs. 2.1%, p = 0.002) (Fig. 3B), which remained significant when patients with progressive disease were excluded (14.1% vs. 2.1%, p = 0.003) (Fig. 3D). **Patterns of hyperenhancement.** Specific patterns of hyperenhancement were evident. There were two broad patterns: diffuse hyperenhancement and confluent hyperenhancement. Patients with diffuse (n = 8) rather than confluent (n = 21) enhancement had ≥2 risk factors for sudden death (87% vs. 33%, p = 0.01). Further classification could be made, but the number of patients is too small to draw strong conclusions. The distributions are shown in Figure 4 and Table 2.

**DISCUSSION**

Identifying patients at high and low risk is an important but problematic aspect of the clinical management of HCM, particularly with the availability of an effective but not hazard-free treatment option—the implantable cardioverter-defibrillator (12). Likewise, there are few markers for the risk of heart failure before LV dysfunction is evident (13,14). Neither the genotype nor the extent of hypertrophy fully predicts the clinical risk (15–17). Ideally, assessment would involve a global assessment of the underlying histology, the substrate for myocardial pump failure, and arrhythmia. The histology consists of myocardial disarray (18) and small-vessel disease or replacement fibrosis (19–21).

Gadolinium-enhanced CMR has been validated for the detection of irreversible injury in myocardial infarction (22). Hyperenhancement is considered to occur in areas of expanded extracellular space. Gadolinium bound to DTPA diffuses into the interstitial space between cells but not across cell membranes. In fibrosis and extracellular expansion, there is a greater extracellular space for gadolinium-DTPA accumulation, and the distribution kinetics are slower than normal myocardium (8,9). These two effects result in a delayed and persistently higher relative concentration of gadolinium in areas in the heart where extracellular tissue is abnormal. We therefore hypothesized that this technique might prove useful in the clinical assessment of the myocardial substrate in HCM. In
Figure 2. Extent of hyperenhancement and presence of progressive disease. Hyperenhancement was associated with the presence of progressive disease (A), even when patients at high risk of sudden death were excluded (B), and appeared more marked in patients >40 years old, regardless of the risk of sudden death (C, D). rfsd = risk factors for sudden death.
Figure 3. Extent of hyperenhancement and clinical risk factors for sudden death. Hyperenhancement was associated with an increased clinical risk of sudden death (A), even when patients with progressive disease were excluded (B), and appeared more marked in patients <40 years old, regardless of the presence of progressive disease (C, D).
myocardial infarction, fibrosis always includes the subendo-
cardium because of the nature of the ischemic wave front
that starts there. In HCM, gadolinium enhancement could
occur in myocardial replacement
fibrosis, but this may
well show different characteristics. First, fibrosis in HCM
can occur throughout the myocardial wall, even with sub-
endocardial sparing. In addition, areas of focal myocardial
disarray and fine interstitial fibrosis may be seen. Therefore,
the distribution and pattern of gadolinium uptake will be
different between these two conditions, as we have con-
firmed in this study.

Histologic correlations between hyperenhancement and
pathology are not yet available. We believe that hyperen-
hancement is the result of a number of pathologic processes
that result in different forms of fibrosis (replacement scar or
myocyte dropout) or in relation to myocardial disarray and
consequent local interstitial expansion. The different pat-
terns of hyperenhancement seen are likely to be linked to
the different pathologic processes occurring in different
patients, and the different stages that such processes had
reached at the time of scanning.

Study limitations. In this preliminary study, the HCM
patients were highly selected, which could introduce a
referral bias. Some patients had both progressive disease
and two or more risk factors for sudden death, but this
reflects the HCM population. Although this compi-
lcated the interpretation of the findings, exclusion of
these patients did not alter the results. Future work is
required to identify histologic correlations and prospec-
tive prediction of events based on hyperenhancement find-
ings.

Conclusions. Areas of hyperenhancement are seen in
HCM by CMR. The extent of hyperenhancement is linked
with progressive disease and markers of clinical risk for
sudden death.

Acknowledgment
The authors thank Professor Philip Poole-Wilson for advice
on trial design and reading of the manuscript.
REFERENCES